IN2015DN03921A - - Google Patents
Info
- Publication number
- IN2015DN03921A IN2015DN03921A IN3921DEN2015A IN2015DN03921A IN 2015DN03921 A IN2015DN03921 A IN 2015DN03921A IN 3921DEN2015 A IN3921DEN2015 A IN 3921DEN2015A IN 2015DN03921 A IN2015DN03921 A IN 2015DN03921A
- Authority
- IN
- India
- Prior art keywords
- release pharmaceutical
- pharmaceutical formulations
- formulations
- oprozomib
- tablets
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010064641 ONX 0912 Proteins 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 abstract 1
- 229950005750 oprozomib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03921A true IN2015DN03921A (cs) | 2015-10-02 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3921DEN2015 IN2015DN03921A (cs) | 2012-10-24 | 2013-10-24 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (cs) |
| EP (1) | EP2912025A4 (cs) |
| JP (1) | JP6505604B2 (cs) |
| KR (1) | KR20150070406A (cs) |
| CN (1) | CN104968650A (cs) |
| AP (1) | AP3681A (cs) |
| AR (1) | AR093126A1 (cs) |
| AU (1) | AU2013334258A1 (cs) |
| BR (1) | BR112015008572A2 (cs) |
| CA (1) | CA2888039A1 (cs) |
| CL (1) | CL2015001085A1 (cs) |
| CR (1) | CR20150266A (cs) |
| EA (1) | EA201590797A1 (cs) |
| HK (2) | HK1208222A1 (cs) |
| IL (1) | IL238244A0 (cs) |
| IN (1) | IN2015DN03921A (cs) |
| MX (1) | MX2015005069A (cs) |
| PE (1) | PE20151051A1 (cs) |
| PH (1) | PH12015500823A1 (cs) |
| SG (1) | SG11201502849XA (cs) |
| TN (1) | TN2015000135A1 (cs) |
| TW (1) | TW201422255A (cs) |
| UY (1) | UY35091A (cs) |
| WO (1) | WO2014066681A1 (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| EP3310344A1 (en) | 2015-06-19 | 2018-04-25 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| JP7065044B2 (ja) | 2016-06-29 | 2022-05-11 | ケザール ライフ サイエンシズ | ペプチドエポキシケトン免疫プロテアソーム阻害剤、およびその前駆体の調製プロセス |
| US20180078532A1 (en) | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
| US20180161279A1 (en) * | 2016-12-14 | 2018-06-14 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| US11401334B2 (en) | 2017-09-14 | 2022-08-02 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| KR20250008774A (ko) | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| US6673838B2 (en) * | 2001-02-12 | 2004-01-06 | Wyeth | Succinate salt of O-desmethyl-venlafaxine |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| CN101405294B (zh) * | 2005-11-09 | 2015-11-25 | 欧尼斯治疗公司 | 用于酶抑制的化合物 |
| WO2007080776A1 (ja) * | 2006-01-10 | 2007-07-19 | Kissei Pharmaceutical Co., Ltd. | 徐放性製剤およびその製造方法 |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| AU2008307510A1 (en) * | 2007-10-04 | 2009-04-09 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en active Application Filing
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2888039A1 (en) | 2014-05-01 |
| US9295708B2 (en) | 2016-03-29 |
| AP2015008387A0 (en) | 2015-04-30 |
| JP2015535255A (ja) | 2015-12-10 |
| IL238244A0 (en) | 2015-06-30 |
| WO2014066681A1 (en) | 2014-05-01 |
| TW201422255A (zh) | 2014-06-16 |
| MX2015005069A (es) | 2015-07-17 |
| AR093126A1 (es) | 2015-05-20 |
| PH12015500823A1 (en) | 2015-06-22 |
| PE20151051A1 (es) | 2015-08-03 |
| KR20150070406A (ko) | 2015-06-24 |
| US20140113855A1 (en) | 2014-04-24 |
| SG11201502849XA (en) | 2015-05-28 |
| US20160213610A1 (en) | 2016-07-28 |
| AU2013334258A1 (en) | 2015-04-30 |
| JP6505604B2 (ja) | 2019-04-24 |
| EA201590797A1 (ru) | 2016-02-29 |
| UY35091A (es) | 2014-05-30 |
| HK1215709A1 (zh) | 2016-09-09 |
| EP2912025A1 (en) | 2015-09-02 |
| CL2015001085A1 (es) | 2015-08-28 |
| TN2015000135A1 (en) | 2016-10-03 |
| BR112015008572A2 (pt) | 2017-07-04 |
| CR20150266A (es) | 2015-08-14 |
| EP2912025A4 (en) | 2016-06-08 |
| AP3681A (en) | 2016-04-19 |
| CN104968650A (zh) | 2015-10-07 |
| HK1208222A1 (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03921A (cs) | ||
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| IN2012DN06720A (cs) | ||
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MY165149A (en) | Use of binders for manufacturing storage stable formulations | |
| PH12012502083A1 (en) | Manufacturing of active-free granules and tablets comprising the same | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| PH12012502082A1 (en) | Combination of active loaded granules with additional actives | |
| PT3003285T (pt) | Forma de administração farmacêutica sólida para libertação de pelo menos dois princípios ativos farmacêuticos na cavidade oral | |
| PT3003383T (pt) | Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| EA201991359A1 (ru) | Фармацевтические лекарственные формы | |
| ZA201500411B (en) | Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process | |
| EA201491477A1 (ru) | Фармацевтические составы, содержащие флупиртин | |
| MY159675A (en) | Clerodane derivatives for modulation of leukotriene receptor activity and related diseases | |
| IN2015MU00907A (cs) | ||
| ES2422657A1 (es) | Composición farmacéutica sólida de cilostazol | |
| WO2014064711A3 (en) | Methods of administering raltegravir and raltegravir compositions | |
| TN2011000018A1 (en) | Pharmaceutical formulations containing dopamine receptor ligands |